A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
Launched by VIRIDIAN THERAPEUTICS, INC. ยท
Trial Information
Current as of November 12, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new medicine called VRDN-003 to see if it is safe and well-tolerated by people with Thyroid Eye Disease (TED), a condition that affects the eyes and can cause swelling, discomfort, and vision problems. The study also looks at how the medicine moves through the body over time. Researchers want to understand if this treatment could be helpful for people with TED.
People of all genders who have Thyroid Eye Disease may be eligible to join, as long as they meet certain age requirements. Participants will receive the study medicine and be closely monitored by the research team to check for any side effects and to see how their bodies respond to the treatment. The trial is currently recruiting volunteers, so if you or a family member has TED and are interested, this might be an option to consider after discussing it with your doctor.
Gender
ALL
Eligibility criteria
About Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with rare and complex diseases. With a commitment to advancing precision medicine, Viridian leverages cutting-edge research and technology to create targeted treatments that address unmet medical needs. The company aims to improve patient outcomes through rigorous clinical trials and collaborations with leading academic institutions and industry partners. With a robust pipeline and a dedicated team of experts, Viridian Therapeutics is poised to make significant contributions to the field of therapeutics and enhance the quality of life for individuals facing challenging health conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported